Anti-Spike Protein (RBD) [CV30]

Absolute Antibody

Anti-Spike Protein (RBD) [CV30]

9

This antibody recognizes and binds the receptor binding domain (RBD) encoded by residues 319-591 of the SARS CoV 2 spike protein. CV30 binds the SARS CoV 2 RBD with a high affinity of 3.6nM and completely blocks the interaction between the RBD and ACE2 do

This antibody is a potent 2019-nCoV neutralizing antibody and highly recommended for diagnosis and/or treatment of SARS CoV 2 or 2019-nCoV. CV30 binds SARS CoV 2 RBD with a very high affinity and achieves 100% neutralization (IC50=0.03microg/ml). ELISA was used to confirm the binding of SARS CoV 2 positive serum samples to the entire ectodomain and the receptor binding domain of the spike protein. Specific binding of the mAb to SARS CoV 2 to receptor binding domain was confirmed with biolayer interferometry. Phycoerythrin labelled mAb was used to stain 293E cells transfected with wild type SARS CoV 2 and were analysed by flow cytometry (Seydoux et al., 2020).

Flow Cytometry, ELISA, Neutralisation/Blocking

Research Use Only

Monoclonal

CV30

S

surface glycoprotein

GU280_gp02; spike glycoprotein; surface glycoprotein

Human

IgE

Spike glycoprotein

This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Virus

-20°C,2°C to 8°C

12352203